To further investigate the usefulness of VEGF121, it is necessary to confirm the results of this study in a prospective cohort of patients with NSCLC who received anti-PD-1/PD-L1 antibody therapy as the first-line treatment. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.